HIV Genetic Diversity and Drug Resistance
Author Information
Author(s): Santos André F., Soares Marcelo A.
Primary Institution: Universidade Federal do Rio de Janeiro
Hypothesis
How does genetic diversity among HIV-1 subtypes affect drug resistance and treatment outcomes?
Conclusion
Different HIV-1 subtypes exhibit distinct patterns of drug resistance and treatment responses.
Supporting Evidence
- HIV-1 subtype B is the most studied but only accounts for 10% of global infections.
- Different HIV subtypes show varying responses to antiretroviral therapy.
- Drug resistance mutations are influenced by the specific HIV subtype.
Takeaway
HIV comes in different types, and some are harder to treat than others because they can resist medications better.
Methodology
This review summarizes laboratory and clinical data on HIV-1 genetic diversity and its implications for drug resistance.
Potential Biases
Potential bias due to the predominance of studies on subtype B, which may not apply to other subtypes.
Limitations
The review primarily focuses on subtype B, which may not represent the full spectrum of HIV diversity.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website